Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa

NCT01715922 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2016-07-12

No results posted yet for this study

Summary

The aim of the trial is to demonstrate that in a sub-Saharan African setting, the association of:

1. Oral treatment : high dose of fluconazole (1600mg/d) associated with flucytosine (100 mg/kg/j) as induction therapy
2. lumbar punctures to control intracranial pressure

can decrease mortality rate below 35% at 10 weeks.

This is a non-randomized open label pilot study, with standardized management of cryptococcoses meningitis and follow-up in Burundi and Ivory Coast. A total of 41 patients will be enrolled.

Conditions

  • Cryptococcal Meningitis
  • HIV

Interventions

DRUG

Fluconazole

Induction treatment for 2 weeks: Fluconazole (1600mg/j) Consolidation treatment for 8 weeks: fluconazole (800 mg/j)

DRUG

Flucytosine

Flucytosine (100 mg/kg/j) for 2 weeks

PROCEDURE

lumbar punctures

lumbar punctures to control intracranial pressure

Sponsors & Collaborators

  • CHU Kamenge, BURUNDI

    collaborator UNKNOWN
  • Hospital Avicenne

    collaborator OTHER
  • Institut Pasteur

    collaborator INDUSTRY
  • Hôpital Necker-Enfants Malades

    collaborator OTHER
  • Institut de Médecine et Epidémiologie Appliquée (IMEA)

    collaborator UNKNOWN
  • Hôpital de Treichville

    collaborator UNKNOWN
  • Hôpital Cocody

    collaborator UNKNOWN
  • ANRS, Emerging Infectious Diseases

    lead OTHER_GOV

Principal Investigators

  • Olivier Bouchaud, PhD · Hopital Avicenne, Service des maladies infectieuses, Paris, france

  • Théodore Niyangobo, PhD · CHU Kamenge, Bujumbura, Burundi

  • Amélie Chabrol, MD · Hopital Avicenne, Service des maladies infectieuses, Paris, france

  • Kakou AKA, Professor · CHU Triechville

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2015-09-30
Completion
2016-09-30

Countries

  • Burundi
  • Côte d’Ivoire

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01715922 on ClinicalTrials.gov